MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

PDL BioPharma Company Profile (NASDAQ:PDLI)

Consensus Ratings for PDL BioPharma (NASDAQ:PDLI) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: $8.00 (30.51% upside)

Analysts' Ratings History for PDL BioPharma (NASDAQ:PDLI)
DateFirmActionRatingPrice TargetActions
8/20/2014Cowen and CompanyBoost Price Target$7.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/5/2013 forward)